You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
328 Phase 3 study of olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab (LYNK-003)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020131015
Dec 20203404
Jan 20213101
Feb 20212804
Mar 202160012
Apr 20213204
May 20211109
Jun 2021006
Jul 2021002
Aug 2021006
Sep 2021004
Oct 202132021
Nov 202164018
Dec 20213206
Jan 20224605
Feb 20224805
Mar 20224003
Apr 20222003
May 20225208
Jun 20224401
Jul 20223804
Aug 20223005
Sep 20222002
Oct 20221401
Nov 20222801
Dec 20222004
Jan 20233001
Feb 20231202
Mar 20232200
Apr 20231200
May 2023802
Jun 2023800
Jul 20231005
Aug 20231401
Sep 2023801
Oct 20231603
Nov 20232202
Dec 20231801
Jan 2024400
Feb 20244802
Mar 20241600
Apr 20241002
May 20242400
Jun 20242803
Jul 20241601
Aug 20241401
Sep 20241603
Oct 20241201
Nov 2024601
Dec 20241600
Jan 20251002
Feb 2025001
Mar 2025004
Apr 2025002
May 2025003
Jun 2025006
Total12550204